ClinicalTrials.gg

Program

Liquid Metformin 100 mg/mL

Its studies are led by Aspargo Labs.

Furthest: phase 1, since Dec 10, 20254 company-led studies, 4 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aspargo Labs44 open or runningphase 1since Dec 10, 2025Dec 10, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 10, 2025First studies: 4 phase 1 studiesFirst studyNCT07300059, NCT07300046, NCT07300033 and 1 more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07300059Healthy Volunteers1Not yet recruitingAug 15, 202624
NCT07300046Healthy Volunteers1Not yet recruitingAug 15, 202624
NCT07300033Healthy Volunteer1Not yet recruitingJul 15, 202624
NCT07300007Healthy Volunteer1Not yet recruitingMay 15, 202624

How it is read

Names in the registry

  • “Liquid Metformin 100 mg/mL”, 4 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.